Treatment of Extramammary Paget Disease with Topical Imiquimod Cream: Case Report and Literature Review

Extramammary Paget disease is an uncommon cutaneous neoplasm that presents as erythematous plaques most frequently located in the anogenital region. Management of patients with extramammary Paget disease involves evaluation of the individual for: (1) a disease-associated, unsuspected, visceral malignancy and (2) secondary adenocarcinoma in the underlying dermis or regional lymph nodes. Several modalities, each with variable effectiveness, are available to treat the cutaneous component of the disease: electrodesiccation and curettage, laser surgery, aminolevulinic acid photodynamic therapy, radiotherapy, topical chemotherapy, and wide surgical excision. However, surgical excision using the Mohs micrographic technique is currently the modality of choice for treating the cutaneous lesions of extramammary Paget disease. Recently, a topical imidazoquinoline immunomodulator that induces cytokine production and stimulates the innate and cellular immune responses—imiquimod cream—has been used for the management of primary or relapsing extramammary Paget disease. Complete healing, without recurrence, of extramammary Paget disease in patients whose cutaneous lesions were treated topically with imiquimod 5% cream was observed. We describe a man with suprapubic extramammary Paget disease whose condition was primary and limited to his skin. Biopsy-confirmed complete resolution of his disease was observed after the topical application of imiquimod 5% cream 3 times per week (on alternate days) for 16 weeks. After reviewing the published reports of other patients with extramammary Paget disease whose disease was successfully treated with imiquimod cream, we suggest that topical imiquimod 5% cream–at least 3 times per week (with 1–2 d of nontreatment in between) for a minimum of 8 to 16 weeks—be considered as an initial treatment for primary cutaneous extramammary Paget disease. Surgical excision or an alternative therapeutic modality is recommended for patients whose extramammary Paget disease persists or recurs after treatment with topical imiquimod.

[1]  S. Tyring,et al.  Current and Potential Uses of Imiquimod , 2005, Southern medical journal.

[2]  T. Hieken,et al.  Successful nonoperative treatment of extensive extramammary Paget's disease , 2005 .

[3]  D. Sauder,et al.  Topical immunotherapy: what's new. , 2005, Dermatologic clinics.

[4]  T. Kirn.  Tx Elusive for Cancer Drug Rash , 2005 .

[5]  D. Brodland,et al.  Extramammary Paget's disease: surgical treatment with Mohs micrographic surgery. , 2004, Journal of the American Academy of Dermatology.

[6]  U. Hengge,et al.  Topical Immunomodulation in Dermatology: Potential of Toll‐like Receptor Agonists , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[7]  A. Huntley,et al.  Imiquimod 5 percent cream and the treatment of cutaneous malignancy. , 2004, Dermatology online journal.

[8]  G. Elgart,et al.  Successful treatment of extramammary Paget's disease of the scrotum with imiquimod 5% cream , 2003, Clinical and experimental dermatology.

[9]  Linda C. Wang,et al.  Successful treatment of recurrent extramammary Paget's disease of the vulva with topical imiquimod 5% cream. , 2003, Journal of the American Academy of Dermatology.

[10]  R. Roenigk,et al.  Comparison of Mohs Micrographic Surgery and Wide Excision for Extramammary Paget's Disease , 2003, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[11]  Allen A. Smith,et al.  Zirconyl hematoxylin vs. alcian blue staining in a case of extramammary Paget's disease , 2003, Journal of cutaneous pathology.

[12]  A. Oseroff,et al.  Successful treatment of extramammary Paget's disease with imiquimod. , 2003, Journal of drugs in dermatology : JDD.

[13]  B. Berman,et al.  Novel dermatologic uses of the immune response modifier imiquimod 5% cream. , 2002, Skin therapy letter.

[14]  F. Flowers,et al.  Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. , 2002, Journal of the American Academy of Dermatology.

[15]  M. Dahl.  Imiquimod: a cytokine inducer. , 2002, Journal of the American Academy of Dermatology.

[16]  Richard L. Miller.  Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors , 2002, International journal of dermatology.

[17]  P. Wolf,et al.  Phase III clinical study demonstrating prevention of skin cancer in xeroderma pigmentosum by topical application of T4N5 liposome lotion containing DNA repair enzymes , 2001 .

[18]  N. J. Mehta,et al.  Extramammary Paget's disease. , 2000, Southern medical journal.

[19]  M. Albom.  American College of Mohs Micrographic Surgery and Cutaneous Oncology , 1996 .

[20]  B. Smoller,et al.  Extramammary Paget's disease: diagnosis and disease pattern. , 1992, Cutis.

[21]  J. Guarner,et al.  Histogenesis of Extramammary and Mammary Paget Cells: An Immunohistochemical Study , 1989, The American Journal of dermatopathology.

[22]  Y. Eliezri,et al.  Role of preoperative topical 5-fluorouracil in preparation for Mohs micrographic surgery of extramammary Paget's disease. , 1987, Journal of the American Academy of Dermatology.